

**May 14, 2026**

**BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
*Scrip Code: 524742*

**National Stock Exchange of India Ltd**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
*Scrip Code: CAPLIPOINT.*

Dear Sir/Madam,

**Sub: Outcome of Board Meeting**

Further to our intimation dated May 07, 2026, we wish to inform you that the Board of Directors, at its meeting held today, has, inter-alia, approved the following:

1. Declared an Interim Dividend of INR. 4.00 (200 %) per equity share of face value of INR. 2 each for the financial year ended March 31, 2026.
2. Fixed May 30, 2026, as Record Date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.
3. Approved the Audited standalone and consolidated financial results (including segment reporting for the consolidated results) of the Company for the year ended March 31, 2026, along with Auditors Report (**Annexure-1**). We also enclose a Press Release issued by the Company (**Annexure-2**) and an investor presentation in this regard (**Annexure-3**).
4. Approved amendments to Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information. The aforesaid code has been made available on the website of the Company at <https://www.caplinpoint.net/index.php/corporate-governance/>

We are also enclosing the information w.r.t. Large Corporate as **Annexure -4**.

We hereby confirm and declare that the Statutory Auditors of the Company i.e., M/s Brahmayya & Co, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2026, with unmodified opinion.

The meeting commenced at 11.10 A.M and concluded at 1.10 P.M.

Kindly take the same on your records.

Sincerely Yours

**For Caplin Point Laboratories Limited**

**Venkatram G**

**General Counsel & Company Secretary**

**Membership No. A23989**

Encl: A/a

**Independent Auditor's Report on Audited Consolidated Quarterly and Annual Financial Results of Caplin Point Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors  
Caplin Point Laboratories Limited

**Report on the Audit of the Consolidated Financial Results**

**Opinion**

We have audited the accompanying consolidated financial results of **Caplin Point Laboratories Limited** (hereinafter referred to as the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associate, for the quarter and year ended 31<sup>st</sup> March, 2026 ("the Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial statements and management accounts of the subsidiaries, and its associate, the Consolidated Financial Results for the quarter and year ended 31<sup>st</sup> March, 2026:

- i. includes the annual financial results of the following entities:

**Subsidiary Companies**

Name of the Entity	Relationship
Caplin Steriles Limited, India	Subsidiary
Argus Salud Pharma LLP, India	Subsidiary
Caplin One Labs Limited, India (Formerly known as Caplin Onco Limited)	Wholly owned subsidiary
Caplin Point Far East Limited, Hong Kong	Wholly owned subsidiary
Caplin Point (S) Pte. Ltd, Singapore	Wholly owned subsidiary

**Step Down Subsidiaries (Subsidiaries of Caplin Point Far East Limited, Hong Kong)**

Name of the Entity	Relationship
Caplin Point EL Salvador, S.A. DE C.V., El Salvador	Step Down Subsidiary
Nuevos Eticos Neo Ethicals S.A, Guatemala	Step Down Subsidiary
Neoethicals CIA.LTDA, Ecuador	Step Down Subsidiary
Drogueria Saimed de Honduras S.A., Honduras	Step Down Subsidiary
Neo Ethicals S.A, Nicaragua	Step Down Subsidiary
Caplin Point Laboratories Colombia SAS, Colombia	Step Down Subsidiary
Neoethicals Chile SpA, Chile	Step Down Subsidiary
Triwin Pharma S.A DE C.V Mexico, Mexico	Step Down Subsidiary



**Step Down Subsidiary (Subsidiary of Caplin Steriles Limited, India)**

Name of the Entity	Relationship
Caplin Steriles USA Inc., USA	Step Down Subsidiary

**Associate Company of Caplin Steriles Limited**

Name of the Entity	Relationship
Sunsole Solar Private Limited	Associate

- ii. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended in this regard; and
- iii. give a true and fair view in conformity with the applicable Indian Accounting Standards (“Ind AS”) and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the quarter and year ended 31<sup>st</sup> March, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Results section of our report.

We are independent of the Group and its associate in accordance with the Code of Ethics issued by Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matters” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

**Management’s Responsibilities for the Consolidated Financial Results**

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associate in accordance with the recognition and measurement principals laid down in Ind AS prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with provisions of the Act for safeguarding of the assets of the Group and its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true

and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the Group and of its associate to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group, or to cease operations or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for overseeing the financial reporting process of the Group and of its associate.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Group and its associate has adequate internal financial controls with reference to statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



- We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group and its associate to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial results of the Holding Company of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matters**

The Statement includes audited financial statement of five subsidiaries and eight step down subsidiaries whose financial statements reflect Group's share of total assets of INR 3,463.44 Crores as at 31<sup>st</sup> March, 2026, Group's share of total revenues of INR 605.12 Crores and INR 2,038.02 Crores and Group's share of total net profit after tax of INR 86.96 Crores and INR 302.97 Crores, and Group's share of total comprehensive income of INR 168.05 Crores and INR 446.79 Crores for the quarter and year ended on that date, respectively and cash flows (net) of INR 44.75 Crores for the year ended 31<sup>st</sup> March, 2026 as considered in the Statement, and the financial statement also includes Group's share of net profit after tax and other comprehensive income of INR 0.003 Crores and INR 0.04 Crores for the quarter and year ended on that date in respect of one associate which have been audited by their respective independent auditors. The independent auditors' reports on financial statements of these entities have been furnished to us by the Management, and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the such auditors and the procedures performed by us as stated in section Basis of Opinion above.

The Statement includes the unaudited financial statement of one step down subsidiary, whose financial statements reflect Group's share of total assets of INR 28.33 Crores as at 31<sup>st</sup> March, 2026, Group's share of total revenue of Nil and INR 0.05 Crores, Group's share of net loss of INR 0.54 Crores and INR 3.33 Crores for the quarter and year ended on that date, respectively and cash flows (net) INR 4.81 Crores for the year ended 31<sup>st</sup> March, 2026 as considered in the statement. These unaudited financial statements have been furnished to us by the Board of Directors and our disclosures included in respect of one step down subsidiary is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial statements are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of other auditors and the financial results certified by the Board of Directors.



The Statement includes the results for the quarter ended 31<sup>st</sup> March, 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

**For Brahmayya & Co.,  
Chartered Accountants  
Firm Registration No. 000511S**



**N. Sri Krishna**

Partner

Membership No. 026575

UDIN: 26026575 JSAMKH 2303

Place : Chennai

Date : May 14, 2026

CAPLIN POINT LABORATORIES LIMITED						
STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2026						
Particulars	Quarter Ended			Year Ended		
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	
	(1)	(2)	(3)	(4)	(5)	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
₹ in Crores						
<b>Income:</b>						
I Revenue from operations	600.16	542.77	502.45	2,187.19	1,937.47	
II Other income	28.36	33.68	25.74	115.54	96.43	
<b>III Total Income (I+II)</b>	<b>628.52</b>	<b>576.45</b>	<b>528.19</b>	<b>2,302.73</b>	<b>2,033.90</b>	
<b>IV Expenses:</b>						
a. Cost of materials consumed	102.11	89.24	73.06	357.20	297.32	
b. Purchase of traded goods	209.02	128.00	126.55	572.20	434.96	
c. Changes in inventories of finished goods, stock in trade and work in progress	(66.13)	(2.10)	1.59	(63.72)	38.56	
d. Employee benefits expense	52.62	52.02	48.16	199.15	184.63	
e. Finance costs	0.36	0.18	0.17	0.87	0.61	
f. Depreciation & Amortisation Expense	18.80	19.28	17.04	72.77	65.96	
g. Other Expenses	98.30	85.92	85.03	361.51	335.07	
<b>Total Expenses</b>	<b>415.08</b>	<b>372.54</b>	<b>351.60</b>	<b>1,499.98</b>	<b>1,357.11</b>	
<b>V Profit before share of profit in Associate, Exceptional Items and tax (III-IV)</b>	<b>213.44</b>	<b>203.91</b>	<b>176.59</b>	<b>802.75</b>	<b>676.79</b>	
VI Share of Profit/(Loss) in Associate	(0.00)	(0.02)	0.08	0.04	(0.01)	
VII Exceptional items	-	-	-	-	-	
<b>VIII Profit Before Tax (V+VI+VII)</b>	<b>213.44</b>	<b>203.89</b>	<b>176.67</b>	<b>802.79</b>	<b>676.78</b>	
<b>IX Tax Expenses</b>						
(1) Current Tax	41.02	35.64	29.27	146.29	125.33	
(2) Deferred Tax	(0.46)	2.39	2.12	6.77	10.36	
<b>Total Tax Expenses</b>	<b>40.56</b>	<b>38.03</b>	<b>31.39</b>	<b>153.06</b>	<b>135.69</b>	
<b>X Net Profit for the period (VIII - IX)</b>	<b>172.88</b>	<b>165.86</b>	<b>145.28</b>	<b>649.73</b>	<b>541.09</b>	
<b>XI Other Comprehensive Income - Net of Tax</b>						
A. Items that will not be re-classified to profit or loss						
i) Remeasurements of Defined Benefit Plan	(0.10)	(0.95)	(0.28)	0.29	0.14	
ii) Income tax relating to these items	0.03	0.24	0.07	(0.07)	(0.04)	
B. Items that will be re-classified to profit or loss						
i) Exchange difference in translating the financial statements of foreign operations	76.97	17.55	(1.54)	141.42	26.97	
<b>XII Total Comprehensive Income For The Period (X + XI)</b>	<b>249.78</b>	<b>182.70</b>	<b>143.53</b>	<b>791.37</b>	<b>568.16</b>	
<b>XIII Profit attributable to:</b>						
Owners of the Company	170.11	163.88	142.57	641.24	536.31	
Non- controlling interests	2.77	1.98	2.71	8.49	4.78	
	<b>172.88</b>	<b>165.86</b>	<b>145.28</b>	<b>649.73</b>	<b>541.09</b>	
<b>XIV Total Comprehensive Income For The Period attributable to</b>						
Owners of the Company	247.01	180.72	140.82	782.88	563.38	
Non- controlling interests	2.77	1.98	2.71	8.49	4.78	
	<b>249.78</b>	<b>182.70</b>	<b>143.53</b>	<b>791.37</b>	<b>568.16</b>	
XV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.20	15.20	15.20	15.20	15.20	
XVI Other equity excluding Non-controlling interest				3,571.22	2,835.29	
<b>XVII Earnings Per Share (EPS) of Face value Rs 2/- per Equity share*</b>						
(a) Basic (in Rupees)	<b>22.38</b>	<b>21.56</b>	<b>18.75</b>	<b>84.36</b>	<b>70.57</b>	
(b) Diluted (in Rupees)	<b>22.31</b>	<b>21.51</b>	<b>18.69</b>	<b>84.11</b>	<b>70.25</b>	
	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Annualised)	*(Annualised)	

See Accompanying notes to Financial Results

BRAHMAYYA & CO.  
For  
Only  
CHARTERED ACCOUNTANTS

CAPLIN POINT LABORATORIES LTD.  
CHENNAI  
600 096.

CAPLIN POINT LABORATORIES LIMITED		
CONSOLIDATED BALANCE SHEET AS AT MARCH 31, 2026		
(All amounts mentioned are in ₹ Crores unless otherwise stated)		
Particulars	(Audited)	(Audited)
	As at March 31, 2026	As at March 31, 2025
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
(a) Property, Plant and Equipment	547.49	530.32
(b) Capital work-in-progress	208.62	139.22
(c) Intangible assets	28.87	11.27
(d) Right of Use Assets	3.65	4.19
(e) Intangible Assets under development	24.96	4.28
(f) Financial Assets		
(i) Investments	473.31	279.13
(ii) Other Financial Assets	28.40	22.20
(g) Income tax assets (Net)	11.30	13.09
(h) Deferred Tax Assets	7.97	5.24
(i) Other Non-Current assets	125.25	67.97
<b>Sub-total-Non current assets</b>	<b>1,459.82</b>	<b>1,076.91</b>
<b>(2) Current Assets</b>		
(a) Inventories	428.86	336.10
(b) Financial Assets		
(i) Investments	385.71	311.33
(ii) Trade Receivables	825.81	632.49
(iii) Cash and Cash equivalents	94.18	199.45
(iv) Bank balances other than (iii) above	526.86	391.96
(v) Other Financial Assets	74.17	57.37
(c) Other Current Assets	250.07	205.25
<b>Sub-total-Current assets</b>	<b>2,585.66</b>	<b>2,133.95</b>
<b>Total</b>	<b>4,045.48</b>	<b>3,210.86</b>
<b>EQUITY AND LIABILITIES</b>		
<b>(1) Equity</b>		
Equity Share capital	15.20	15.20
Instruments entirely equity in nature	74.58	74.58
Other Equity	3,496.64	2,760.71
<b>Equity attributable to shareholders of the company</b>	<b>3,586.42</b>	<b>2,850.49</b>
Non controlling interest	44.38	35.90
<b>Sub-total-Equity</b>	<b>3,630.80</b>	<b>2,886.39</b>
<b>(2) Liabilities</b>		
<b>(A) Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Lease Liabilities	2.06	2.91
(b) Deferred Tax Liabilities	12.60	3.01
(c) Provisions	1.00	1.74
(d) Other non current liabilities	13.08	10.82
<b>Sub-total-Non current liabilities</b>	<b>28.74</b>	<b>18.48</b>
<b>(B) Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	0.57	0.55
(ii) Trade Payables		
(a) total outstanding dues of micro and small enterprises	9.26	2.28
(b) total outstanding dues other than (ii) (a) above	286.77	215.30
(iii) Lease Liabilities	1.98	1.56
(iv) Other financial Liabilities	50.76	45.26
(b) Provisions	20.02	23.58
(c) Other Current Liabilities	16.58	17.46
<b>Sub-total-Current liabilities</b>	<b>385.94</b>	<b>305.99</b>
<b>Total</b>	<b>4,045.48</b>	<b>3,210.86</b>



CAPLIN POINT LABORATORIES LIMITED  
CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH 2026  
(All amounts are in ₹ Crores unless otherwise stated)

Particulars	(Audited)	(Audited)
	For the year ended Mar 31, 2026	For the year ended Mar 31, 2025
<b>A. Cash Flow from Operating Activities</b>		
Profit before tax	802.79	676.78
<b>Adjustments for:</b>		
Depreciation and Amortisation expense	72.77	65.96
Finance costs	0.87	0.61
Government grant	(2.38)	(2.10)
(Profit)/Loss on sale/disposal of property, plant and equipment	4.18	3.76
Employee Stock option Scheme Expense	(1.33)	9.38
Net Unrealised Foreign Exchange Fluctuation Loss (Gain)	(14.85)	(3.46)
Fair value (gain)/loss on financial instruments through profit or loss	(2.14)	(1.11)
Realised gain on Financial Assets	(5.51)	(3.90)
Share of Profit in Associate	(0.04)	0.01
Interest income	(77.64)	(63.64)
<b>Operating Profit before Working Capital changes</b>	<b>776.72</b>	<b>682.29</b>
<b>Adjustments for :</b>		
(Increase) / Decrease in inventories	(92.76)	26.94
(Increase) / Decrease in Trade receivables	(178.71)	(87.75)
(Increase) / Decrease in Other Financial assets	(3.43)	(2.34)
(Increase) / Decrease in Other assets	(44.52)	(54.33)
Increase / (Decrease) in Trade payables, Other Liabilities & Provisions	69.01	(31.77)
Impact of Foreign currency translation	141.42	26.97
<b>CASH GENERATED FROM OPERATIONS</b>	<b>667.73</b>	<b>560.01</b>
Income tax Paid (Net)	(144.50)	(127.64)
<b>Net Cash inflow / (outflow) from Operating activities (A)</b>	<b>523.23</b>	<b>432.37</b>
<b>B. Cash Flow from Investing Activities</b>		
Payment for Acquisition of subsidiaries (Net)	(0.05)	-
Sale / (Purchase) of investments	(266.38)	(213.76)
Investment / (Redemption) in Bank Deposits & Inter corporate Debenture	(1.85)	(7.15)
(Increase) / Decrease in Other Bank Balances	(134.89)	22.08
Sale / (Purchase) of property, plant and equipment (Including CWIP)	(248.13)	(191.52)
Interest received	62.40	51.72
Realised gain on Financial Assets	5.51	3.90
Increase / (Decrease) in Other Financial Assets	1.10	-
<b>Net Cash inflow / (outflow) from Investing activities (B)</b>	<b>(582.29)</b>	<b>(334.73)</b>
<b>C. Cash Flow from Financing Activities</b>		
Proceeds from exercise of employee stock options	-	0.01
Increase / (Decrease) in Long and Short term Borrowings	0.02	0.27
Interest paid (Including interest on Lease liability)	(0.87)	(0.61)
Dividend paid	(45.61)	(37.99)
<b>Net Cash inflow / (outflow) from Financing activities (C)</b>	<b>(46.46)</b>	<b>(38.32)</b>
<b>Net increase / (decrease) in cash and cash equivalents during the period (D=A+B+C)</b>	<b>(105.52)</b>	<b>59.32</b>
<b>Cash and Cash Equivalents as at the beginning of the period (E)</b>	<b>199.45</b>	<b>138.70</b>
Effect of exchange rate changes on cash and cash equivalents (F)	0.25	1.43
<b>Cash and Cash Equivalents as at the end of the period (G=D+E+F)</b>	<b>94.18</b>	<b>199.45</b>
Less: Bank Balance in Unspent CSR Account (H)	7.54	5.71
<b>Net Cash and Cash Equivalents as at the end of the period (I=G-H)</b>	<b>86.64</b>	<b>193.74</b>



**CAPLIN POINT LABORATORIES LIMITED**  
**Segment Information (Consolidated)**

Particulars	Quarter Ended			Year Ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	(1)	(2)	(3)	(4)	(6)
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
₹ in Crores					
<b>1) Segment revenue (Total Revenue)</b>					
Rest of the World	470.25	432.93	406.12	1,733.79	1,582.96
USA	129.91	109.84	96.33	453.40	354.51
Unallocated	28.36	33.68	25.74	115.54	96.43
<b>Total</b>	<b>628.52</b>	<b>576.45</b>	<b>528.19</b>	<b>2,302.73</b>	<b>2,033.90</b>
<b>2) Segment results (PBT)</b>					
Rest of the World	163.32	160.30	135.33	631.20	540.34
USA	21.76	9.91	15.60	56.05	40.01
Unallocated	28.36	33.68	25.74	115.54	96.43
<b>Total</b>	<b>213.44</b>	<b>203.89</b>	<b>176.67</b>	<b>802.79</b>	<b>676.78</b>
<b>3) Segment Assets</b>					
Rest of the World	1,918.28	1,720.07	1,448.25	1,918.28	1,451.26
USA	656.00	617.91	580.09	656.00	580.09
Unallocated	1,471.20	1,380.58	1,179.51	1,471.20	1,179.51
<b>Total</b>	<b>4,045.48</b>	<b>3,718.56</b>	<b>3,207.85</b>	<b>4,045.48</b>	<b>3,210.86</b>
<b>4) Segment Liabilities</b>					
Rest of the World	332.52	273.05	271.19	332.52	271.19
USA	82.16	65.55	53.28	82.16	53.28
Unallocated	-	-	-	-	-
<b>Total</b>	<b>414.68</b>	<b>338.60</b>	<b>324.47</b>	<b>414.68</b>	<b>324.47</b>



## CAPLIN POINT LABORATORIES LIMITED

### Consolidated Notes:

- 1) The above Audited Consolidated Financial Results for the quarter and year ended March 31, 2026, have been recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on May 14, 2026.
- 2) The Audited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA). Accordingly, segment reporting has been presented along with the Consolidated results.
- 4) Details of number of shares allotted under Employee Stock Option Plan (ESOP):

Particulars	Number of Shares				
	Quarter Ended			Year Ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
Shares Allotted under Employee Stock Option Plan (ESOP)	-	-	-	-	69,950
Total Number of Equity Shares of the Company	7,60,11,696	7,60,11,696	7,60,11,696	7,60,11,696	7,60,11,696

- 5) Pursuant to the notification of the New Labour Codes effective 21st November, 2025 by Government of India whereby multiple existing labour legislations have been consolidated into a unified framework, the Company has assessed the implications of the revised definition of "wages" for employees. The assessment has resulted in an increase in gratuity and compensated absence related employee benefit obligations aggregating to ₹1.39 Crores. The impact has been recognized in the financial results for the quarter ended December 31, 2025, and accordingly forms part of the financial results for the year ended March 31, 2026.

The Company continues to monitor developments pertaining to the New Labour Codes, and the impact thereof, if any, will be accounted for in accordance with applicable accounting standards.

- 6) The Board of Directors at their meeting held on May 14, 2026 approved an interim dividend of ₹ ~~4~~ **200**.%) per equity share of ₹ 2 each for the Financial Year 2025-26.
- 7) The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year, which have been subjected to limited review by the Statutory auditors.
- 8) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary.

For and on behalf of the Board

Place: Chennai  
Date: May 14, 2026



Dr. Sridhar Ganesan  
Managing Director

**Independent Auditor's Report on Audited Standalone Quarterly and Annual Financial Results  
of Caplin Point Laboratories Limited pursuant to Regulation 33 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors  
Caplin Point Laboratories Limited

**Report on the Audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone financial results of **Caplin Point Laboratories Limited** ("the Company") for the quarter and year ended 31<sup>st</sup> March, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015. as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us. the Statement:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended 31<sup>st</sup> March ,2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act,2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report.

We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the audited standalone annual financial statements. The Company's Board of Directors are responsible for the preparation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS prescribed under Section 133 of



the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Company's Board of Directors are also responsible for overseeing the Company's Financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143 (3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required

to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a Statement that we have complied with relevant ethical requirement regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matters

The Statement includes the results for the quarter ended 31<sup>st</sup> March , 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

**For Brahmayya & Co.,**  
**Chartered Accountants**  
Firm Registration No. 000511S



**N. Sri Krishna**  
Partner

Membership No. 026575

UDIN: 26026575HHZEEF4088

Place : Chennai  
Date : May 14, 2026

CAPLIN POINT LABORATORIES LIMITED						
STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2026						
Particulars	Quarter Ended			Year Ended		
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	
	(1)	(2)	(3)	(4)	(5)	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
₹ In Crores						
<b>Income:</b>						
<b>I</b> Revenue from operations	191.36	189.22	173.61	738.33	752.41	
<b>II</b> Other income	61.08	31.73	41.25	195.37	134.59	
<b>III Total Income (I+II)</b>	<b>252.44</b>	<b>220.95</b>	<b>214.86</b>	<b>933.70</b>	<b>887.00</b>	
<b>IV Expenses:</b>						
a. Cost of materials consumed	45.80	39.47	34.25	158.82	136.64	
b. Purchase of traded goods	24.67	23.45	17.39	82.51	77.17	
c. Changes in inventories of finished goods, stock in trade and work in progress	(14.89)	(5.80)	3.66	(12.37)	24.36	
d. Employee benefits expense	13.15	13.41	14.39	47.72	52.13	
e. Finance costs	0.05	0.07	0.04	0.20	0.12	
f. Depreciation & Amortisation Expense	6.90	6.37	6.09	25.43	24.77	
g. Other Expenses	39.04	26.97	28.88	123.87	130.14	
<b>Total Expenses</b>	<b>114.72</b>	<b>103.94</b>	<b>104.70</b>	<b>426.18</b>	<b>445.33</b>	
<b>V Profit before exceptional items and Tax (III-IV)</b>	<b>137.72</b>	<b>117.01</b>	<b>110.16</b>	<b>507.52</b>	<b>441.67</b>	
<b>VI</b> Exceptional items	-	-	-	-	-	
<b>VII Profit Before Tax (V-VI)</b>	<b>137.72</b>	<b>117.01</b>	<b>110.16</b>	<b>507.52</b>	<b>441.67</b>	
<b>VIII Tax Expenses</b>						
(1) Current Tax	26.45	29.35	23.63	109.49	102.90	
(2) Deferred Tax	1.77	0.38	0.03	1.45	(0.72)	
<b>Total Tax Expenses</b>	<b>28.22</b>	<b>29.73</b>	<b>23.66</b>	<b>110.94</b>	<b>102.18</b>	
<b>IX Net Profit for the period (VII-VIII)</b>	<b>109.50</b>	<b>87.28</b>	<b>86.50</b>	<b>396.58</b>	<b>339.49</b>	
<b>X Other Comprehensive Income/ (Loss) - Net of Tax</b>						
A. Items that will not be re-classified to profit or loss						
i) Remeasurements of Defined Benefit Plan	(0.17)	(0.58)	(0.29)	(0.09)	(0.13)	
ii) Income tax relating to these items	0.04	0.15	0.07	0.02	0.03	
<b>XI Total Comprehensive Income For The Period (IX+X)</b>	<b>109.37</b>	<b>86.85</b>	<b>86.28</b>	<b>396.51</b>	<b>339.39</b>	
<b>XII</b> Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.20	15.20	15.20	15.20	15.20	
<b>XIII</b> Other equity				2,035.30	1,685.73	
<b>XIV Earnings Per Share (EPS) of Face value Rs 2/- per Equity share*</b>						
(a) Basic (in Rupees)	15.89	11.49	11.37	52.17	44.67	
(b) Diluted (in Rupees)	15.85	11.46	11.35	52.02	44.47	
	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Annualised)	*(Annualised)	

See Accompanying notes to Financial Results



<b>CAPLIN POINT LABORATORIES LIMITED</b>		
<b>STANDALONE BALANCE SHEET AS AT MARCH 31, 2026</b>		
<b>(All amounts mentioned are in ₹ Crores unless otherwise stated)</b>		
<b>Particulars</b>	<b>(Audited)</b>	<b>(Audited)</b>
	<b>As at March 31, 2026</b>	<b>As at March 31, 2025</b>
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
(a) Property, plant and equipment	219.68	201.59
(b) Capital work-in-progress	9.39	20.64
(c) Intangible assets	1.24	2.10
(d) Right of Use Assets	2.00	1.57
(e) Financial assets		
(i) Investments	704.73	491.11
(ii) Loans	267.54	245.80
(iii) Other Financial Assets	18.04	18.81
(f) Income tax assets (Net)	2.82	2.90
(g) Other Non-current Assets	10.42	4.27
<b>Sub-total-Non current assets</b>	<b>1,235.86</b>	<b>988.79</b>
<b>(2) Current Assets</b>		
(a) Inventories	85.66	66.26
(b) Financial assets		
(i) Investments	342.51	311.33
(ii) Trade receivables	265.96	175.33
(iii) Cash and cash equivalents	44.09	99.64
(iv) Bank balances other than (iii) above	161.99	115.07
(v) Other Financial Assets	39.42	25.92
(c) Other current assets	36.25	32.14
<b>Sub-total-Current assets</b>	<b>975.88</b>	<b>825.69</b>
<b>Total</b>	<b>2,211.74</b>	<b>1,814.48</b>
<b>EQUITY AND LIABILITIES</b>		
<b>(1) Equity</b>		
(a) Equity share capital	15.20	15.20
(b) Other equity	2,035.30	1,685.73
<b>Sub-total-Equity</b>	<b>2,050.50</b>	<b>1,700.93</b>
<b>(2) Liabilities</b>		
<b>(A) Non-Current Liabilities</b>		
(a) Financial liabilities		
(i) Lease Liabilities	1.34	1.13
(b) Deferred tax liabilities (Net)	10.67	9.25
(c) Other non current liabilities	2.85	2.47
(d) Provisions	2.21	0.85
<b>Sub-total-Non current liabilities</b>	<b>17.07</b>	<b>13.70</b>
<b>(B) Current Liabilities</b>		
(a) Financial liabilities		
(i) Trade payables		
(a) total outstanding dues of micro and small enterprises	4.46	1.78
(b) total outstanding dues other than micro and small enterprises	88.56	59.18
(ii) Lease Liabilities	0.85	0.53
(iii) Other financial Liabilities	19.77	16.50
(b) Provisions	9.10	10.68
(c) Other Current liabilities	21.43	11.18
<b>Sub-total-Current liabilities</b>	<b>144.17</b>	<b>99.85</b>
<b>Total</b>	<b>2,211.74</b>	<b>1,814.48</b>



**CAPLIN POINT LABORATORIES LIMITED**  
**STANDALONE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026**  
(All amounts are in ₹ Crores unless otherwise stated)

Particulars	(Audited)	(Audited)
	For the year ended March 31, 2026	For the Year Ended Mar 31,2025
<b>A. Cash Flow from Operating Activities</b>		
Profit before tax	507.52	441.67
Adjustments for:		
Depreciation and Amortisation expense	25.43	24.77
Finance costs	0.20	0.12
Government grant	(0.64)	(0.71)
(Profit)/Loss on sale/disposal of property, plant and equipment	4.14	3.91
Employee Stock Option Scheme Expense	(1.38)	6.46
Net Unrealised Foreign Exchange Fluctuation Loss (Gain)	(14.85)	(3.46)
Fair value loss on financial instruments through profit or loss	(1.85)	(1.11)
Realised gain on Financial Assets	(3.75)	(3.48)
Dividend Income	(62.30)	(35.53)
Interest Income	(77.51)	(75.44)
<b>Operating Profit before Working Capital changes</b>	<b>375.01</b>	<b>357.20</b>
Adjustments for:		
(Increase) / Decrease in Inventories	(19.40)	19.99
(Increase) / Decrease in Trade receivables	(76.03)	(44.62)
(Increase) / Decrease in Other Assets	(4.11)	(11.33)
(Increase) / Decrease in Other Financial assets	(0.34)	(0.78)
Increase / (Decrease) in Trade payables ,Other Liabilities & Provisions	49.06	(20.75)
<b>Cash Generated from Operations</b>	<b>324.19</b>	<b>299.71</b>
Income tax Paid	(109.41)	(103.84)
<b>Net Cash inflow / (outflow) from Operating activities</b>	<b>214.78</b>	<b>195.87</b>
<b>B. Cash Flow from Investing Activities</b>		
Sale / (Purchase) of Investments	(226.90)	(210.26)
Investment in Bank Deposits & Inter Corporate Deposits	(1.85)	(7.15)
Investment in Subsidiaries	(16.00)	(4.00)
Loan- repayment by/(given to) Subsidiary (net)	(21.74)	16.20
(Increase)/Decrease in Other Bank Balances	(46.67)	20.10
Sale / (Purchase) of property, plant and equipment (Including CWIP)	(44.63)	(56.56)
Interest received	66.97	62.46
Dividend received	62.30	35.53
Realised gain on Financial Assets	3.75	3.48
<b>Net Cash inflow/(outflow) from Investing activities</b>	<b>(224.77)</b>	<b>(140.20)</b>
<b>C. Cash Flow from Financing Activities</b>		
Proceeds from exercise of employee stock options	-	0.01
Interest paid (Including interest on Lease liability)	(0.20)	(0.12)
Dividend paid	(45.61)	(37.99)
<b>Net Cash inflow / (outflow) from Financing activities</b>	<b>(45.81)</b>	<b>(38.10)</b>
<b>Net increase / (decrease) in cash and cash equivalents during the period D=(A+B+C)</b>	<b>(55.80)</b>	<b>17.57</b>
<b>Cash and Cash Equivalents as at the beginning of the period (E)</b>	<b>99.64</b>	<b>80.64</b>
Effect of exchange rate changes on cash and cash equivalents (F)	0.25	1.43
<b>Cash and Cash Equivalents as at the end of the period (G=D+E+F)</b>	<b>44.09</b>	<b>99.64</b>
Less: Bank Balance in Unspent CSR Account (H)	7.00	5.71
<b>Net Cash and Cash Equivalents as at the end of the period (I=G-H)</b>	<b>37.09</b>	<b>93.93</b>



## **CAPLIN POINT LABORATORIES LIMITED**

### **Standalone Notes:**

- 1) The above Audited Standalone financial Results for the quarter and year ended March 31, 2026 were recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 14, 2026.
- 2) The Audited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore no separate segment reporting is applicable to the Company.
- 4) Other Income and Profit Before Tax includes:

Particulars	₹ In Crores				
	Quarter Ended			Year Ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
Dividend from wholly owned subsidiary Caplin Point Far East Limited	30.55	-	15.14	62.30	35.53

- 5) Details of number of shares allotted under Employee Stock Option Plan (ESOP):

Particulars	Number of Shares				
	Quarter Ended			Year Ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
Shares Allotted under Employee Stock Option Plan (ESOP)	-	-	-	-	69,950
Total Number of Equity Shares of the Company	7,60,11,696	7,60,11,696	7,60,11,696	7,60,11,696	7,60,11,696

- 6) Pursuant to the notification of the New Labour Codes effective 21st November, 2025 by Government of India whereby multiple existing labour legislations have been consolidated into a unified framework, the Company has assessed the implications of the revised definition of "wages" for employees. The assessment has resulted in an increase in employee benefit obligations relating to gratuity and compensated absences aggregating to ₹0.84 crores. The impact has been recognized in the financial results for the quarter ended December 31, 2025, and accordingly forms part of the financial results for the year ended March 31, 2026. The Company continues to monitor developments pertaining to the New Labour Codes, and the impact thereof, if any, will be accounted for in accordance with applicable accounting standards.
- 7) The Board of Directors at their meeting held on May 14, 2026 approved an interim dividend of ~~₹ 4~~ **200.0%** per equity share of ₹ 2 each for the FY 2025-26.
- 8) The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year, which have been subjected to limited review by the Statutory auditors.
- 9) Previous periods' figures have been regrouped / reclassified to be in conformity with current period's classification / disclosure, wherever necessary.

Place: Chennai  
Date: May 14, 2026



For and on behalf of the Board

*(Signature)*  
Dr. Sridhar Ganesan  
Managing Director

**Total revenue of ₹2,303 Crores; an increase of 13.2% YoY**

**PAT of ₹650 Crores; an increase of 20.1% YoY**

**US market revenue of ₹471 Crores, recording 28.7% growth YoY.**

**Free Cash Reserves at ₹1,471 Crores; Liquid Assets at ₹2,726 Crores.**

**Chennai, 14<sup>th</sup> May 2026:** Caplin Point Laboratories Ltd. (“Caplin Point” or the “Company”) (BSE: 524742 | NSE: CAPLIPOINT), a rapidly expanding and fully integrated pharmaceutical company with a leading market position in Latin America, today announced its financial performance for the quarter and year ended March 31, 2026.

**Consolidated Financial Performance for Q4FY26 & 12M FY26:**

₹ in Crores

Particulars	Q4 FY 26	Q4 FY 25	YoY (%)	Q3 FY 26	QoQ (%)	12M FY26	12M FY25	YoY (%)
Revenue from Operations	600.2	502.5	19.4%	542.8	10.6%	2,187.2	1,937.5	12.9%
Total Revenue	628.5	528.2	19.0%	576.5	9.0%	2,302.7	2,033.9	13.2%
Gross Profit	355.2	301.3	17.9%	327.6	8.4%	1,321.5	1,166.6	13.3%
<i>Gross Margin %</i>	<i>59.2%</i>	<i>60.0%</i>		<i>60.4%</i>		<i>60.4%</i>	<i>60.2%</i>	
EBITDA	232.6	193.8	20.0%	223.4	4.1%	876.4	743.4	17.9%
<i>EBITDA Margin %</i>	<i>37.0%</i>	<i>36.7%</i>		<i>38.7%</i>		<i>38.1%</i>	<i>36.5%</i>	
Profit Before Tax	213.4	176.7	20.8%	203.9	4.7%	802.8	676.8	18.6%
<i>PBT Margin %</i>	<i>34.0%</i>	<i>33.4%</i>		<i>35.4%</i>		<i>34.9%</i>	<i>33.3%</i>	
Profit after Tax	172.9	145.3	19.0%	165.9	4.2%	649.7	541.1	20.1%
<i>PAT Margin</i>	<i>27.5%</i>	<i>27.5%</i>		<i>28.8%</i>		<i>28.2%</i>	<i>26.6%</i>	

**Other Consolidated Financial Highlights:**

- Gross Margin remains strong, standing at 60.4% for 12M FY26 compared to 60.2% in 12M FY25.
- EBITDA Margin for 12M FY26 increased to 38.1% vs 36.5% in 12M FY25.
- Basic EPS increased by 19.5% to ₹84.36 in 12M FY26 compared to ₹70.57 in 12M FY25.
- Cash Flow from Operations in 12M FY26 is ₹523 Crores vs ₹432 Crores in 12M FY25.
- Free Cash Flow is ₹275 Crores (after Capex investment of ₹248 Crores) in 12M FY26 as compared to ₹241 Crores (after capex investment of ₹191 Crores) in 12M FY25.
- Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for 12M FY26 is in the range of 79% and 21% respectively.
- CSL’s Revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for 12M FY26 in the range of 80% and 20% respectively.
- As at 31<sup>st</sup> March 2026, Inventories are at ₹429 Crores - 50% Stock at the warehouses, close to the customer; In Transit 16%; 34% in India. Receivables stood at 136 days, with the increase primarily attributable to foreign exchange rate on closing date, without this impact receivables would have stood at 125 days.
- As at 31<sup>st</sup> March 2026, Free Cash reserves are at ₹1,471 Crores and Total Liquid Assets at ₹2,726 Crores.

How Company Grew in Last 5 and 10 Years				
Particulars	10 Years CAGR	5 Years CAGR	2015-16 to 2025-26	2020-21 to 2025-26
Operating Revenue	21.6%	15.6%	310 Cr to 2187 Cr	1061 Cr to 2187 Cr
Total Revenue	22.1%	16.2%	313 Cr to 2303 Cr	1085 Cr to 2303 Cr
EBITDA	26.0%	20.0%	87 Cr to 876 Cr	352 Cr to 876 Cr
PBT	26.5%	20.7%	77 Cr to 803 Cr	314 Cr to 803 Cr
PAT	27.3%	21.0%	58 Cr to 650 Cr	251 Cr to 650 Cr
Free Cash Reserves			68 Cr to 1471 Cr	470 Cr to 1471 Cr

### **Business Highlights for Q4 FY26:**

#### **Emerging Markets:**

- Caplin's consistent growth engine of Latin America continues robust and profitable growth across multiple segments.
- Mexico Update – Company has received approvals for 25 products with a pipeline of 120+ products to be filed within the next 18 months, from CPL, COL and CSL's internal pipeline. Company has won 11 General and Oncology products for Tenders supply in Mexico over the next 24 months, with a total value of \$4 million. Company working on building plans and approvals for constructing its own facility in Mexico for Dermatology and Oral Liquids products. This facility will cater to both North and South Americas.
- Chile Update – Company continues robust progress with tender and private market sales in Chile. Caplin already holds 135+ product licenses in Chile, with several more under review/pipeline. Company has won 15 products for Tenders supplies over the next 24 months, with a total value of around \$10 million. Caplin will setup its own Quality Release Lab in Chile in the next 12-18 months, a move to increase profitability and speed to market for new launches.
- Company enters Brand Marketing in CNS segment in 3 markets of LatAm. Aims to extend to 2 more markets in 2027. Company has also launched a lineup of Branded Pre-Filled Syringe products in LatAm, a unique value addition to its growing portfolio.
- Caplin's "China 2.0" strategy of partnering with Companies that have ANDAs/MAs approved in US and EU shows good progress. Through this partnership, multiple products have been filed across Mexico, Colombia and Chile, in addition to its first Biosimilar product filing in Central America. Company has signed partnerships with multiple Chinese companies, granting access to 110+ approved ANDAs/MAs in the US and EU. These products will be extended to all Latin American countries, under Caplin's name.
- Oncology Unit update – Company's new Oncology facility completes first Regulatory inspection successfully. Company has acquired several ANDAs in Oncology segment from 3<sup>rd</sup> parties. These products, along with internally developed pipeline products in both OSD and Injectable segments, will be submitted for approval across multiple markets in 2026/27.

- Vizag API Unit update – Caplin’s General Category API unit, to be used predominantly for backward integration, has received manufacturing license and has completed validations for 4 APIs already. Plans on track to complete validations for 12 more APIs before end of the year. First few DMF filings from this site will be done in 2026/27. Company aims to have its own API for around 60% of its Regulated markets pipeline in 4-5 years.
- Thervoy Oncology API unit update – Facility will be completed for validations by Q3-FY27. First DMF filings from this site planned in FY28.
- Company awaits approvals from several Central American countries for its own internally developed GLP-1 products. Company plans to expand GLP-1 range of products to other South American markets in (post patents expiry) FY28.
- Amaris Clinicals update – Progress ongoing to increase the clinical trials to 3 studies per month from the existing 2 studies per month. All the products are from Company’s own internal pipeline.

### **US & Regulated Markets:**

- Caplin Steriles Limited (CSL) continues excellent growth across all parameters. Current split between B2B and B2C segments is 75% & 25%
- Caplin has received 10 ANDA approvals in FY26, and has also acquired 15 ANDAs from 3<sup>rd</sup> party companies (including 5 in COL name) taking its ANDA tally to 59, a jump of 25 ANDAs over FY25. These approvals and acquisitions cover a large portion of the Sterile products spectrum including Vials, IV Bags, Ophthalmic and Otic drops, Pre-Filled Syringes, Suspensions (both Injectable and Ophthalmic), Emulsions (both Injectable and Ophthalmic), Oncology and Hormonal products.
- Company’s development pipeline remains strong, with around 15 products likely to be filed in US within FY27, predominantly in Pre-Filled Syringes and Ophthalmic segments.
- CSL has filed 54 products (of which 32 are approved) in multiple Non-US markets, such as Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi, UAE etc. Plans in place to file 50+ products in these regions in the next 18 months. Meaningful revenue is expected out of these markets in FY27.
- Company expands capacity of IV Bag lines to 3X the current size, since multiple products have been approved in this niche segment.
- As part of Company’s original pattern of “growth through Asset Light/Outsourcing model”, Company is working with highly compliant CMO’s to takeover high volume/price sensitive injectable products, for US, which are currently being manufactured in-house.
- Company enters highly niche and complex Blow Fill Seal technology segment, with the first product development nearing completion. This segment will cater to Unit Dose Ophthalmics and Sterile Inhalation products, of which the company has a development pipeline of over 14 products.
- Company’s unique patent pending “Project Visual Integration” takes shape with a vision to Go Live within 3 months at CSL’s entire site. This project will ensure complete integration and monitoring of all critical processes making significant progress in Caplin’s continuous push towards Automation and Compliance. This project will eventually be rolled out across all Caplin group’s plants in the future.
- To cater the growing capacity needs at CSL, company’s COL-II facility construction will be completed by Dec ’26 to house 5 Injectable, Ophthalmic and BFS lines. Provision to add 3 more lines also included in the construction.

- **Update on Caplin Steriles USA Inc (CSU) - company's own label in the US:**

- CSU completes first full year of operations with around \$11 million in revenue and 26.2% in EBIDTA, a sizeable feat for a “startup” entity. Company achieves profitability and self-sustaining cashflow within first year of operations.
- CSU has launched 30 products till date and plans to launch 15 more products in the current year, a mix of injectable suspensions, Injectables in PP Vials and multiple IV Bags.
- CSU continues consistent supplies through both direct and indirect sales, with all major Wholesalers and IDNs across the US.
- Caplin Group plans to establish a separate retail arm in the US, focused on its Ophthalmic products pipeline, Unit Dose Ophthalmics and Inhalations pipeline, in addition to Oral Solid products licensed from recent partnerships with Chinese companies with approved ANDAs.

**Commenting on the performance, Mr. C.C. Paarthipan, Chairman said:**

The financial year FY26 has been another year of steady progress and disciplined execution for the Company. We have delivered strong financial performance, with sustained margins, healthy cash generation, and consistent growth across our key markets. The strength of our unique end-to-end business model is showcased clearly by the consistency of these numbers, at a larger base also.

Our Emerging Markets business continues to be a reliable growth engine, driven by deep market presence, expanding product portfolios, and increasing participation in institutional channels. At the same time, we are making meaningful strides in strengthening our footprint in Regulated Markets, particularly in the United States, where Caplin Steriles is gaining scale and depth.

During the year, we made significant investments in building future capabilities — across manufacturing, automation, compliance strengthening, backward integration, product development, and regulatory filings. Our progress in Oncology, APIs, and complex dosage forms such as Pre-Filled Syringes and Blow-Fill-Seal technology, positions us well for the next phase of growth. Importantly, these investments are being made while maintaining strong cash flows and a robust balance sheet. We remain debt-free and will continue to remain so.

We are also encouraged by the early success of Caplin Steriles USA, our front-end initiative in the US, which achieved profitability within its first year of operations — an outcome that reflects both execution discipline and the strength of our product selection. This was done without a de-growth in our B2B business, which shows our discipline in capacity utilization and ensuring consistent supply across segments.


As we look ahead, our focus remains clear: to build a diversified and resilient business across geographies, deepen our presence in complex and differentiated products, and continue investing in quality, compliance, and automation. Initiatives such as our backward integration program, expansion into new technologies, and digital transformation efforts will play a critical role in strengthening our competitive position.

While we remain optimistic about the opportunities ahead, we will continue to approach growth with prudence and discipline, staying aligned with our core principles of sustainable and profitable expansion. I would like to thank our employees for their dedication, our partners for their continued trust, and our shareholders for their unwavering support.

### Strategic Growth Initiatives

Project Summary					
Facility	Location	Product	Target Market	Status	Timeline
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes.	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	OSD – Completed Injectable – Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity Completed.	Q4 FY27
OSD Facility	Puducherry	Oral Solid Dosages	New Markets such as Mexico, Brazil, US and EU	Civil activity ongoing at full swing.	Q1 FY28
COL Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmics	Regulated Markets	Civil & Structural activity ongoing at full swing.	Q4 FY27

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process.



#### Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. G`ummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam

#### About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company also has a growing presence in the regulated markets such as US through its Subsidiary Caplin Steriles Limited and Caplin Steriles USA Inc.

Caplin Point listed on Forbes “Asia’s 200 Best Under a Billion” list for 2024. Company has appeared for the **SEVENTH** time on this list (2014, 2015, 2016, 2021, 2022, 2023 and 2024) and was awarded “The Emerging Company of 2018” by Economic Times Family Business Awards.

For further information, please contact:

**G Venkatram,**  
*General Counsel & Company Secretary*  
Caplin Point Laboratories

+91 44 2496 8000

[investor@caplinpoint.net](mailto:investor@caplinpoint.net)

**Simran Malhotra / Soham Arora**  
Churchgate Partners

+91 99454 72589

[caplinpoint@churchgatepartners.com](mailto:caplinpoint@churchgatepartners.com)

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Caplin Point Laboratories Ltd, nor its directors, or any of its subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.



Caplin Point  
Laboratories Limited

# EARNINGS PRESENTATION Q4 FY26


Rated #1 in India for *“Most Consistent Profitable Growth across the last 10 years”*

*Second Largest wealth creator for the decade ending 2020\**

May 2026

[www.caplinpoint.net](http://www.caplinpoint.net)






# Evolution Over the Decades








## Contract manufacturer

-  Market-led Company
-  Plain vanilla generic products
-  Introducing products that plugged marketplace gaps
-  Negative-working capital business
-  2 main geographies 10 countries (Latin America & Francophone Africa)


## Becoming a responsible pharma company

-  Technology and research-led marketing Company
-  Mix of generics, branded generics and specialty molecules and Injectables
-  Launch specialty niche products that Create new markets in varied therapy segments
-  Selective use of Credit strategy to increase market share and remain cash surplus
-  Extended to Regulated markets like USA with recent entry into Canada, Australia, Mexico and Brazil shortly


## Diversified Product Portfolio

-  5,000+ Products registered and 650+ Pharmaceutical formulations
-  36 Therapeutic Segments
-  Product mix covers over 65% of WHO essential drug list
-  Latest focus towards complex spaces
-  Accounts for larger shelf share across pharmacies on account of a widening product basket


## Revenue from Operations




## Gross Profit




## EBITDA




## EBIT




## PAT




## Earnings Per Share




## Gross Profit Margins (%)




## EBITDA Margins (%)




## EBIT Margins (%)




## PAT Margins (%)




## Revenue from Operations




## Gross Profit




## EBITDA




## EBIT



## PAT



## Profit Margins



## Chairman Perspectives



Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Point Laboratories said:

“The financial year FY26 has been another year of steady progress and disciplined execution for the Company. We have delivered strong financial performance, with sustained margins, healthy cash generation, and consistent growth across our key markets. The strength of our unique end-to-end business model is showcased clearly by the consistency of these numbers, at a larger base also.

Our Emerging Markets business continues to be a reliable growth engine, driven by deep market presence, expanding product portfolios, and increasing participation in institutional channels. At the same time, we are making meaningful strides in strengthening our footprint in Regulated Markets, particularly in the United States, where Caplin Steriles is gaining scale and depth.

During the year, we made significant investments in building future capabilities – across manufacturing, automation, compliance strengthening, backward integration, product development, and regulatory filings. Our progress in Oncology, APIs, and complex dosage forms such as Pre-Filled Syringes and Blow-Fill-Seal technology, positions us well for the next phase of growth. Importantly, these investments are being made while maintaining strong cash flows and a robust balance sheet. We remain debt-free and will continue to remain so.

We are also encouraged by the early success of Caplin Steriles USA, our front-end initiative in the US, which achieved profitability within its first year of operations – an outcome that reflects both execution discipline and the strength of our product selection. This was done without a de-growth in our B2B business, which shows our discipline in capacity utilization and ensuring consistent supply across segments.

As we look ahead, our focus remains clear: to build a diversified and resilient business across geographies, deepen our presence in complex and differentiated products, and continue investing in quality, compliance, and automation. Initiatives such as our backward integration program, expansion into new technologies, and digital transformation efforts will play a critical role in strengthening our competitive position.

While we remain optimistic about the opportunities ahead, we will continue to approach growth with prudence and discipline, staying aligned with our core principles of sustainable and profitable expansion. I would like to thank our employees for their dedication, our partners for their continued trust, and our shareholders for their unwavering support.”

## Management Team

Dr. Sridhar Ganesan

- Managing Director



Mr. D Muralidharan

- Chief Financial Officer



# Q4 FY26 Highlights (Emerging Markets)

01

Caplin's consistent growth engine of Latin America continues robust and profitable growth across multiple segments

02

Mexico Update - Company has received approvals for 25 products with a pipeline of 120+ products to be filed within the next 18 months, from CPL, COL and CSL's internal pipeline. Company has won 11 General and Oncology products for Tenders supply in Mexico over the next 24 months, with a total value of \$4 million

03

Chile Update - Company continues robust progress with tender and private market sales in Chile. Caplin already holds 135+ product licenses in Chile, with several more under review/pipeline. Company has won 15 products for Tenders supplies over the next 24 months, with a total value of around \$10 million

04

Company enters Brand Marketing in CNS segment in 3 markets of LatAm. Aims to extend to 2 more markets in 2027. Company has also launched a lineup of Branded Pre-Filled Syringe products in LatAm, a unique value addition to its growing portfolio

05

Caplin's "China 2.0" strategy of partnering with Companies that have ANDAs/MAs approved in US and EU shows good progress. Through this partnership, multiple products have been filed across Mexico, Colombia and Chile, in addition to its first Biosimilar product filing in Central America. Company has signed partnerships with multiple Chinese companies

## Emerging Markets Business Highlights

Oncology Unit update - Company's new Oncology facility completes first Regulatory inspection successfully. Company has acquired several ANDAs in Oncology segment from 3rd parties. These products, along with internally developed pipeline products in both OSD and Injectable segments

06

Vizag API Unit update - Caplin's General Category API unit, to be used predominantly for backward integration, has received manufacturing license and has completed validations for 4 APIs already. Plans on track to complete validations for 12 more APIs before end of the year

07

Thervoy Oncology API unit update - Facility will be completed for validations by Q3-FY27. First DMF filings from this site planned in FY28

08

Company awaits approvals from several Central American countries for its own internally developed GLP-1 products. Company plans to expand GLP-1 range of products to other South American markets in (post patents expiry) FY28

09

Amaris Clinicals update - Progress ongoing to increase the clinical trials to 3 studies per month from the existing 2 studies per month. All the products are from Company's own internal pipeline

10

# Q4 FY26 Highlights (US and Regulated markets)

01

Caplin Steriles Limited (CSL) continues excellent growth across all parameters. Current split between B2B and B2C segments is 75% & 25%

02

Caplin has received 10 ANDA approvals in FY26, and has also acquired 15 ANDAs from 3rd party companies (including 5 in COL name) taking its ANDA tally to 59, a jump of 25 ANDAs over FY25

03

Company's development pipeline remains strong, with around 15 products likely to be filed in US within FY27, predominantly in Pre-Filled Syringes and Ophthalmic segments

04

CSL has filed 54 products (of which 32 are approved) in multiple Non-US markets, such as Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi, UAE etc. Plans in place to file 50+ products in these regions in the next 18 months. Meaningful revenue is expected out of these markets in FY27

05

Company expands capacity of IV Bag lines to 3X the current size, since multiple products have been approved in this niche segment

## Emerging Markets Business Highlights

As part of Company's original pattern of "growth through Asset Light/Outsourcing model", Company is working with highly compliant CMO's to takeover high volume/price sensitive injectable products, for US, which are currently being manufactured in-house

06

Company enters highly niche and complex Blow Fill Seal technology segment, with the first product development nearing completion. This segment will cater to Unit Dose Ophthalmics and Sterile Inhalation products, of which the company has a development pipeline of over 14 products

07

Company's unique patent pending "Project Visual Integration" takes shape with a vision to Go Live within 3 months at CSL's entire site. This project will ensure complete integration and monitoring of all critical processes making significant progress in Caplin's continuous push towards Automation and Compliance

08

To cater the growing capacity needs at CSL, company's COL-II facility construction will be completed by Dec '26 to house 5 Injectable, Ophthalmic and BFS lines. Provision to add 3 more lines also included in the construction


09

Caplin Group plans to establish a separate retail arm in the US, focused on its Ophthalmic products pipeline, Unit Dose Ophthalmics and Inhalations pipeline, in addition to Oral Solid products licensed from recent partnerships with Chinese companies with approved ANDAs



10

# Research & Development Capabilities

- 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved).
- 2 Continuous capex investment of over Rs. 870 Cr over last 5 years towards enhanced manufacturing and R&D capabilities, from internal accruals.
- 3 Total R&D Spends (Capex + Opex) is 15.5% of FY26 PAT.
- 4 Caplin ranks amongst the top companies in India, for R&D spend as a percentage of Revenue on average in the past 5 years.\*
- 5 Completed R&D for 90+ APIs to be used for backward integration in US and Emerging markets. First DMF filing targeted by end of FY2027.



**356**  
Strength of R&D Team




\*Source – CNBC-TV18, Dec 31st 2020

\*Including Partners and Bought Out


# Revenue Break up and Manufacturing Strategy

**FY26 Operating Revenue**




■ Africa ■ US ■ LATAM

**Revenue by Business Segment (Emerging Markets)**



■ Generic ■ Branded Generic


**Revenue by Channel (Emerging Markets)**



■ Wholesale ■ Retail ■ Institutional


Caplin covers a wide spectrum of pharmaceutical formulations and therapeutic segments across 23 countries with total revenue of Rs. 2,303 Cr in FY26

**Manufacturing & Outsourcing**



■ Inhouse Production ■ Outsourced Production

**Exports**



■ India ■ China

Caplin’s smart strategy of balanced manufacturing and outsourcing makes it possible to be a lean organisation as well as de-risk against cost escalations, currency fluctuations and other headwinds

# Generics and Branded Generics Product Mix



Non-Steroidal Antiinflammatory Drugs-NSAIDS



Anthelmintics/ Dewormer



Analgesic



Antibiotic and Antifungal



Antihypertensive drug



Electrolytes

## Caplin Point Laboratories (BSE: 524742| NSE: CAPLIPOINT)

### Manufacturing Units:

- CP I: Puducherry
- CP X: Vishakhapatnam

### Research & Development:

- CP III: Amaris Clinical CRO, Chengalpattu
- CP VI: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Hyderabad
- CP VII: TICEL Bio-Park Bioequivalent dosage forms, Taramani, Chennai
- CP VIII: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Perungudi, Chennai

## Subsidiaries of CPL

- Caplin Point Far East Ltd
- Caplin Steriles Limited (CSL)
- Caplin One Labs Limited (COL)
- Argus Salud Pharma LLP
- Caplin Point (S) Pte Ltd

## Caplin Point Far East Ltd

### Subsidiaries

- Nuevos Eticos Neo Ethicals S.A. Guatemala
- Neo Ethicals S.A. Nicaragua
- Drogueria Saimed de Honduras S.A
- Caplin Point El Salvador, S.A. DE C.V.
- Neoethicals CIA. LTDA Ecuador
- Caplin Point Laboratories Colombia SAS
- Neo Ethicals Chile SpA.
- Triwin Pharma S.A DE C.V Mexico

## Caplin One Labs Ltd (COL)

### Manufacturing Unit:

- SIDCO, Kakkalur (Near Chennai)
- Gummidipoondi, Chennai

## Caplin Steriles Ltd (India)

### Manufacturing Units:

- CP IV: Gummidipoondi

### Research & Development:

- Perungudi, Chennai
- Gummidipoondi


- Sunsole Solar Private Ltd (Associate of CSL)

## Caplin Steriles USA Inc (US)

### Distribution:

- Front-end trading arm for the sale of products in the USA

Tamil Nadu, India



## Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam

Andhra Pradesh, India



CP I  
Puducherry



CP III  
Chengalpattu



CP IV  
Gummidipoondi



CP VI  
Hyderabad



Corporate Office and other  
R&D units:  
Chennai



CP VII  
Chennai

Note. CP III and CP VII are for Research and Development

Project Summary					
Facility	Location	Product	Target Market	Status	Timeline
Caplin Plant I	CPI, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	OSD – Completed Injectable – Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity completed	Q4 FY27
OSD Facility	Puducherry	Oral Solid Dosages	New Market such as Mexico, Brazil, US and EU	Civil activity ongoing at full swing	Q1 FY28
COL Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmics	Regulated Markets	Civil & Structural activity ongoing at full swing	Q4 FY27

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process

## Core Business to show consistent growth

Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at a steady pace with industry-average margins and benchmark cashflows

## US Business to Boost the Growth

Aspiration is to have exceptional compliance record and focus on niche products which continues to be in shortage in US market. Caplin believes US business to be one of its primary engines that will drive growth

## Backed by Enhanced Value Chain

Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings

## Strong Balance Sheet

Caplin's DNA of remaining debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long-term vision

## Expansion into Other Geographies and Widening of the Portfolio

Caplin plans to enter more regulated markets such as Canada, Australia, MENA, Russia/CIS as well as enter the bigger LATAM markets of Mexico and Brazil in the near to medium term horizon

Strong operational performance driven by key pillars of Caplin's Engines

# Experienced and Visionary Board of Directors (1/2)



**Mr. C.C. Paarthipan**  
*Chairman*

30+ Years of experience in the pharmaceutical industry

Spearheading the group in its multi-pronged growth approach

First Gen Entrepreneur with a focus towards bottom of the pyramid



**Dr. Sridhar Ganesan**  
*Managing Director*

35+ Years experience in Pharmaceutical Industry

Previously, held leadership positions in several international assignments

The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"

Has been a Faculty in BITS



**Mr. Ashok Partheeban**  
*Vice Chairman*

23+ Years experience in Pharmaceutical Industry

Oversees the entire LATAM operations since 2002 as well as other emerging markets

Spearheaded market expansion and growth initiatives in the LATAM region

Holds an Associate's Degree in OPM from Harvard Business School and a Bachelor's in Marketing from Middlesex University



**Mr. Vivek Partheeban**  
*Vice Chairman*

20+ years of experience in the pharmaceutical industry

Was COO at Caplin Point Laboratories Ltd, Oversees the entire U.S/regulated market. operations

Educated at Harvard Business School and Monash University

Honorary Consul for the Republic of Guatemala in Chennai since 2018



**Dr. KC John**  
*Independent Director*

35+ years of experience in sustainable development

Held leadership roles in start-ups, tech ventures, and acquisitions

Expert for Tamil Nadu Industrial Development Corporation

Doctorate in Management from Indian Institute of Management, Ahmedabad



**Dr. R Nagendran**

*Independent Director*

Ph.D in Ecology and Ethology and M.SC in Zoology

Former Expert Member of the National Green Tribunal and former Head of Department of Environmental Science in St. Joseph's College, Bangalore.



**Mr S Deenadayalan**

*Independent Director*

Post Graduate degree in Social Work from Madras School of Social Work and Under Graduate degree in Sociology from Annamalai University

Has extensively worked and mentors individuals enabling them to become successful professionals and more than 30,000 municipal school students have been benefitted by his idealistic model.



**Mr. R. Vijayaraghavan**

*Independent Director*

35+ years of experience as a taxation expert with consulting and litigation practice across India

Advises major corporate groups in South India on Direct Taxes, Tax Planning, Tax Litigations

Specializes in advising on taxation of non-residents, joint ventures & collaborations, double taxation avoidance agreements & transfer pricing issues.



**Mrs. Susan Mathew**

*Independent Director*

Post Graduate degree from Union Christian College and Graduate of Women's Christian College, Chennai

Served 36 years in senior IAS positions, including as Principal Secretary to the Governor

She contributed to key policies like private power projects and the Comprehensive Transport Policy in Tamil Nadu


# Q4 FY26 Consolidated Income Statement

In Rs. Crores

Particulars	Q4 FY26	Q4 FY25	YoY (%)	Q3 FY26	QoQ (%)	FY26	FY25	YoY (%)
Revenue from Operation	600.16	502.45	19.4%	542.77	10.6%	2,187.19	1,937.47	12.9%
Other Income	28.36	25.74	10.2%	33.68	(15.8%)	115.54	96.43	
<b>Total Revenue</b>	<b>628.52</b>	<b>528.19</b>	<b>19.0%</b>	<b>576.45</b>	<b>9.0%</b>	<b>2,302.73</b>	<b>2,033.90</b>	<b>13.2%</b>
Cost of Goods sold	245.00	201.20	21.8%	215.14	13.9%	865.68	770.84	12.3%
<b>Gross Profit (Excluding Other Income)</b>	<b>355.16</b>	<b>301.25</b>	<b>17.9%</b>	<b>327.63</b>	<b>8.4%</b>	<b>1,321.51</b>	<b>1,166.63</b>	<b>13.3%</b>
<i>Gross Profit Margin (on Rev from Operations)</i>	<b>59.2%</b>	<b>60.0%</b>		<b>60.4%</b>		<b>60.4%</b>	<b>60.2%</b>	
Employee Benefit Expenses	52.62	48.16	9.3%	52.02	1.2%	199.15	184.63	7.9%
Research and Development expenses	19.94	19.68	1.3%	20.54	(2.9%)	79.89	76.68	4.2%
Other operating expenses	78.36	65.35	19.9%	65.38	19.9%	281.62	258.39	9.0%
<b>Total expenditure</b>	<b>150.92</b>	<b>133.19</b>	<b>13.3%</b>	<b>137.94</b>	<b>9.4%</b>	<b>560.66</b>	<b>519.70</b>	<b>7.9%</b>
<b>EBITDA</b>	<b>232.60</b>	<b>193.80</b>	<b>20.0%</b>	<b>223.37</b>	<b>4.1%</b>	<b>876.39</b>	<b>743.36</b>	<b>17.9%</b>
<i>EBITDA Margin</i>	<b>37.0%</b>	<b>36.7%</b>		<b>38.7%</b>		<b>38.1%</b>	<b>36.5%</b>	
Depreciation and Amortisation	18.80	17.04	10.3%	19.28	(2.5%)	72.77	65.96	10.3%
<b>EBIT</b>	<b>213.80</b>	<b>176.76</b>	<b>21.0%</b>	<b>204.09</b>	<b>4.8%</b>	<b>803.62</b>	<b>677.40</b>	<b>18.6%</b>
<i>EBIT Margin</i>	<b>34.0%</b>	<b>33.5%</b>		<b>35.4%</b>		<b>34.9%</b>	<b>33.3%</b>	
Finance Cost	0.36	0.17		0.18		0.87	0.61	
Share of Profit/(Loss) in associates	(0.00)	0.08		(0.02)		0.04	(0.01)	
<b>Profit Before Tax</b>	<b>213.44</b>	<b>176.67</b>	<b>20.8%</b>	<b>203.89</b>	<b>4.7%</b>	<b>802.79</b>	<b>676.68</b>	<b>18.6%</b>
<i>PBT Margin</i>	<b>34.0%</b>	<b>33.4%</b>		<b>35.4%</b>		<b>34.9%</b>	<b>33.3%</b>	
Tax	40.56	31.39		38.03	6.7%	153.06	135.69	12.8%
<b>Profit after Tax</b>	<b>172.88</b>	<b>145.28</b>	<b>19.0%</b>	<b>165.86</b>	<b>4.2%</b>	<b>649.73</b>	<b>541.09</b>	<b>20.1%</b>
<i>PAT Margin</i>	<b>27.5%</b>	<b>27.5%</b>		<b>28.8%</b>		<b>28.2%</b>	<b>26.6%</b>	

At the core of our ethos lies a steadfast commitment to embedding environmental, social, and governance principles into our operations.

Click to access ESG Profile



Map our ESG framework with 35+ different frameworks

Download ESG data

Access to ESG factsheet

Search for keywords

Over 12 factors and 400+ KPI



Home The Company Infrastructure Products Investors Sustainability Careers Contact Us

- CSR Trust
- CSR Activities
- Policies
- ESG Profile

Caplin Point Providing Remedies  
**BRINGING SMILES**  
To People

Caplin Point ESG Profile Link ([Click Here](#))

<https://www.caplinpoint.net/>

### ESG Commitments

- **Community Development**
  - ✓ Caplin Group’s state-of-the-art hospital and diagnostic centre at Gummidipoondi, Chennai
- **Recycled Waste**
  - ✓ 60.2 MT waste recycled in 2025
- **Environmental & Social**
  - ✓ Low carbon footprint
  - ✓ Women empowerment
  - ✓ Investments in rural healthcare

### CSR

**INR 8.49 Crores**  
Amount spent on CSR in FY25

**INR 4.16 Crores**  
Amount spent on CSR in FY26

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Caplin Point Laboratories Ltd.



Caplin Point  
Laboratories Limited

Mr G Venkatram

[investors@caplinpoint.net](mailto:investors@caplinpoint.net)

Churchgate  
Investor Relations

Simran Malhotra / Soham Arora

+91 99454 72589

[caplinpoint@churchgatepartners.com](mailto:caplinpoint@churchgatepartners.com)

**BSE** 524742

**NSE** CAPLIPOINT

CIN: L24231TN1990PLC019053

ISIN: INE475E01026 | DUNS:86-148-4556 | [WWW.CAPLINPOINT.NET](http://WWW.CAPLINPOINT.NET)

©2018, Caplin Point Laboratories Limited – All Rights Reserved.

“Caplin Point” and The Caplin Point Logo are trademarks of Caplin Point Laboratories Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.



**May 14, 2026****BSE Limited**Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
*Scrip Code: 524742***National Stock Exchange of India Ltd**Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
*Scrip Code: CAPLIPOINT.*

Dear Sir/Madam,

**Sub: Disclosure of information w.r.t. Large Corporate**

With reference to SEBI circular no. SEBI/HO/DDHS/DDHS-RACPODI/P/CIR/2023/172 dated October 19, 2023, and pursuant to email communication received from the Stock Exchanges please find below the details:

Symbol	NSE: CAPLIPOINT; BSE: 524742
Company Name	Caplin Point Laboratories Limited
Financial From	1 <sup>st</sup> April 2025
Financial To	31 <sup>st</sup> March 2026
Outstanding Qualified Borrowings at the start of the financial year (Rs. In Crores)	NIL
Outstanding Qualified Borrowings at the end of the financial year (Rs. In Crores)	NIL
Credit rating (highest in case of multiple ratings)	NA
Incremental borrowing done during the year (qualified borrowings) (Rs. In Crores)	NA
Borrowings by way of issuance of debt securities during the year (Rs. In Crores)	NA

Note: The information pertaining to the outstanding borrowings are provided as on March 31, 2026.

Kindly take the same on your records.

Sincerely Yours

**For Caplin Point Laboratories Limited**

**Venkatram G**  
**General Counsel & Company Secretary**  
**Membership No. A23989**